Professor Jun Guo: Addressing Unmet Clinical Needs to Explore a New Treatment Approach for Favorable-Risk Renal Cell Carcinoma — Balancing Tumor Control with Long-Term Tolerability: The Rationale Behind Ivonescimab

Professor Jun Guo: Addressing Unmet Clinical Needs to Explore a New Treatment Approach for Favorable-Risk Renal Cell Carcinoma — Balancing Tumor Control with Long-Term Tolerability: The Rationale Behind Ivonescimab

During the 2026 European Society for Medical Oncology (ESMO) Congress, first-line treatment options for patients with favorable-risk advanced renal cell carcinoma (RCC) attracted considerable attention. For this patient population, how to control disease while reducing the burden of long-term treatment remains an important question warranting further investigation. Oncology Frontier – UroStream invited Professor Jun Guo of Peking University Cancer Hospital to discuss the patient selection, dual-target blockade strategy, and potential clinical value of ivonescimab.
4th One Health | Professor Patrick Harris: Clinical Trials for Multidrug-Resistant Gram-Negative Bacteria—Current Landscape, Challenges, and Future Directions

4th One Health | Professor Patrick Harris: Clinical Trials for Multidrug-Resistant Gram-Negative Bacteria—Current Landscape, Challenges, and Future Directions

Infections caused by multidrug-resistant Gram-negative bacteria have become a major threat to global public health, yet clinical research on the related antibacterial agents has long been confronted with challenges such as complex trial design, pronounced heterogeneity of resistance mechanisms, and unequal access to drugs. At the 4th One Health Conference of Antimicrobial Resistance Containment, Professor Patrick Harris of the Royal Brisbane and Women's Hospital, Australia, gave a dedicated presentation entitled "Clinical Trials in Multidrug-Resistant Gram-Negative Bacteria — Where Are We? What Do We Need?" Infectious Disease Frontier invited Professor Patrick Harris for an in-depth dialogue on the difficulties of clinical trial design, progress in novel agents, international collaboration, and infection prevention and control.
Professors Qi Zhou and Li Yuan Discuss Four Studies: ADCs Show Promise in Platinum-Resistant Ovarian Cancer, While New Breakthroughs Emerge in Precision Biomarker Development

Professors Qi Zhou and Li Yuan Discuss Four Studies: ADCs Show Promise in Platinum-Resistant Ovarian Cancer, While New Breakthroughs Emerge in Precision Biomarker Development

Ovarian cancer is often referred to as the "king of gynecologic cancers." Platinum-resistant recurrent ovarian cancer (PROC) remains a major clinical challenge. Once platinum resistance develops, conventional single-agent chemotherapy offers low response rates and poor prognosis, leaving patients with limited treatment options. In recent years, the emergence of antibody-drug conjugates (ADCs) and targeted small-molecule agents has begun to reshape the treatment landscape of platinum-resistant ovarian cancer.
ESMO Voices from China | Professors Dawei Tian and Jianing Guo: HER2 Expression Heterogeneity in Bladder Carcinoma In Situ Reveals New Therapeutic Opportunities in Urothelial Carcinoma Beyond Invasive Disease

ESMO Voices from China | Professors Dawei Tian and Jianing Guo: HER2 Expression Heterogeneity in Bladder Carcinoma In Situ Reveals New Therapeutic Opportunities in Urothelial Carcinoma Beyond Invasive Disease

In recent years, HER2-targeted antibody–drug conjugates (ADCs), including disitamab vedotin, have demonstrated significant clinical value in the treatment of urothelial carcinoma (UC). However, HER2 expression in UC exhibits spatiotemporal heterogeneity. Bladder carcinoma in situ (CIS), in particular, is characterized by its occult presentation, high malignancy, and substantial risk of progression to invasive carcinoma. A standardized HER2 testing workflow for CIS is currently lacking, highlighting the need for further investigation. To address this challenge, a research team led by Professor Dawei Tian and Professor Jianing Guo of the Second Hospital of Tianjin Medical University conducted a clinical study whose findings were selected for presentation at the annual congress of the European Society for Medical Oncology (ESMO) [1], providing new evidence in this field. Oncology Frontier – UroStream invited both professors to discuss the clinical value of HER2, the characteristics of HER2 expression in CIS, the potential of disitamab vedotin in UC, and the implications of their findings for HER2 testing and clinical management.
17th Yanzhao Breast Cancer Forum | Professor Shusen Wang: From MECCA to SYSUCC-020—Endocrine Therapy Plus Metronomic Chemotherapy Opens a New Chapter in HR-Positive/HER2-Negative Breast Cancer Treatment

17th Yanzhao Breast Cancer Forum | Professor Shusen Wang: From MECCA to SYSUCC-020—Endocrine Therapy Plus Metronomic Chemotherapy Opens a New Chapter in HR-Positive/HER2-Negative Breast Cancer Treatment

Hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer is the most common molecular subtype of breast cancer. For decades, the combination of endocrine therapy and chemotherapy was considered a therapeutic “forbidden zone” because of its theoretical basis and early clinical evidence. With the emergence of novel endocrine agents, chemotherapeutic drugs, antibody–drug conjugates (ADCs), and evolving treatment strategies, this traditional view is gradually being challenged. In recent years, metronomic chemotherapy has emerged as a promising approach to combining chemotherapy with endocrine therapy because of its distinctive antiangiogenic and immunomodulatory mechanisms and favorable safety profile. The MECCA and SYSUCC-020 studies have provided important evidence supporting this strategy in the first-line setting and among patients previously treated with CDK4/6 inhibitors, respectively.
CSCO 2026 | Professor Wenyu Li: Current Treatment Landscape and Controversies in Newly Diagnosed Mantle Cell Lymphoma

CSCO 2026 | Professor Wenyu Li: Current Treatment Landscape and Controversies in Newly Diagnosed Mantle Cell Lymphoma

The 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan from September 16 to 19, 2026, bringing together oncology experts from around the world to explore advances in precision diagnosis and treatment. During the lymphoma session, Professor Wenyu Li of Guangdong Provincial People's Hospital delivered a presentation entitled “Current Treatment Landscape and Controversies in Newly Diagnosed Mantle Cell Lymphoma (MCL).” Drawing on the 2025 EHA–EU MCL Network guidelines, the 2026 CSCO guidelines, and several pivotal clinical studies, Professor Li examined three major controversies in first-line MCL treatment: whether transplant-eligible patients still require autologous stem cell transplantation (ASCT) in the BTK inhibitor (BTKi) era; treatment options for older or transplant-ineligible patients; and precision treatment strategies for high-risk patients, including those with TP53 mutations. This article summarizes the key points of the presentation.
Professor Wenming Chen: Advances in the Application of Bispecific Antibodies in Multiple Myeloma | 2026 Cross-Strait Hematology Academic Conference

Professor Wenming Chen: Advances in the Application of Bispecific Antibodies in Multiple Myeloma | 2026 Cross-Strait Hematology Academic Conference

The treatment landscape for multiple myeloma continues to evolve with successive advances in immune-targeted therapies. As a novel class of immunotherapeutic agents, bispecific antibodies have helped address major treatment challenges in patients with relapsed or refractory disease and have become a key focus of research in multiple myeloma. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, on August 21–22. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Wenming Chen of Beijing Chao-Yang Hospital, Capital Medical University, to discuss the evolving role of bispecific antibodies in multiple myeloma, strategies for combination and sequential treatment, and the latest evidence presented at the 2026 European Hematology Association (EHA) Congress in the context of current clinical research in China. His insights offer practical guidance for the standardized, effective, and individualized use of bispecific antibodies to maximize treatment efficacy and safety for patients.
CSCO DocX TALK | Upholding Core Principles and Driving Innovation: Professor Heinz-Josef Lenz and HUTCHMED Discuss the Globalization of China’s Innovative Oncology Drugs

CSCO DocX TALK | Upholding Core Principles and Driving Innovation: Professor Heinz-Josef Lenz and HUTCHMED Discuss the Globalization of China’s Innovative Oncology Drugs

The 2026 Chinese Society of Clinical Oncology (CSCO) Annual Meeting showcased cutting-edge advances in oncology worldwide, with China's innovative drug development attracting particular attention. China has become an increasingly important force in global cancer research and treatment. During the meeting, Oncology Frontier invited Professor Heinz-Josef Lenz of USC Norris Comprehensive Cancer Center and Mr. George Yuan, Executive Vice President of HUTCHMED, to engage in an in-depth dialogue under the theme “Upholding Core Principles and Driving Innovation: Moving Forward Together.”